blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3302709

EP3302709 - METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.03.2022
Database last updated on 30.09.2024
FormerThe patent has been granted
Status updated on  16.04.2021
FormerGrant of patent is intended
Status updated on  08.12.2020
FormerExamination is in progress
Status updated on  30.03.2020
FormerRequest for examination was made
Status updated on  09.03.2018
FormerThe international publication has been made
Status updated on  09.12.2016
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Temple University - Of The Commonwealth System of Higher Education
Broad Street and Montgomery Avenue
Philadelphia, PA 19122 / US
[2018/15]
Inventor(s)01 / KHALILI, Kamel
190 Presidential Boulevard Apt. 718
Bala Cynwyd, PA 19004 / US
02 / HU, Wenhui
224 Europa Court
Cherry Hill, NJ 08003 / US
03 / ZHANG, Yonggang
48e Village of Stoney Run
Maple Shade, NJ 08052 / US
 [2018/15]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2021/20]HGF
1 City Walk
Leeds LS11 9DX / GB
Former [2018/15]HGF Limited
8th Floor
140 London Wall
London EC2Y 5DN / GB
Application number, filing date16804274.501.06.2016
[2018/15]
WO2016US35141
Priority number, dateUS201562169384P01.06.2015         Original published format: US 201562169384 P
US201562169633P02.06.2015         Original published format: US 201562169633 P
US201662308320P15.03.2016         Original published format: US 201662308320 P
[2018/15]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016196539
Date:08.12.2016
Language:EN
[2016/49]
Type: A2 Application without search report 
No.:EP3302709
Date:11.04.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 08.12.2016 takes the place of the publication of the European patent application.
[2018/15]
Type: B1 Patent specification 
No.:EP3302709
Date:19.05.2021
Language:EN
[2021/20]
Search report(s)International search report - published on:US16.02.2017
(Supplementary) European search report - dispatched on:EP21.12.2018
ClassificationIPC:C12N15/113, A61K31/7088, // A61P31/18
[2020/47]
CPC:
A61K38/465 (EP,KR,US); A61K48/00 (KR,US); A61P31/18 (EP,KR,US);
C12N15/11 (US); C12N15/1132 (EP,KR,US); C12N15/907 (US);
C12N9/22 (EP,KR,US); C12N2310/10 (KR,US); C12N2310/20 (EP,KR,US);
C12N2320/11 (KR,US) (-)
Former IPC [2019/04]C12N15/113, A61K31/712
Former IPC [2018/15]A61P31/18, A61K48/00, C12N5/10, C12N15/63, C12N9/22
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/15]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN RNA-GEFÜHRTEN BEHANDLUNG VON HIV-INFEKTIONEN[2018/15]
English:METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION[2018/15]
French:MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT GUIDÉ PAR ARN DE L'INFECTION PAR LE VIH[2018/15]
Entry into regional phase06.12.2017National basic fee paid 
06.12.2017Search fee paid 
06.12.2017Designation fee(s) paid 
06.12.2017Examination fee paid 
Examination procedure06.12.2017Examination requested  [2018/15]
06.12.2017Date on which the examining division has become responsible
17.07.2019Amendment by applicant (claims and/or description)
02.04.2020Despatch of a communication from the examining division (Time limit: M06)
07.08.2020Reply to a communication from the examining division
09.12.2020Communication of intention to grant the patent
09.04.2021Fee for grant paid
09.04.2021Fee for publishing/printing paid
09.04.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21172750.8  / EP3919622
Opposition(s)22.02.2022No opposition filed within time limit [2022/17]
Fees paidRenewal fee
12.06.2018Renewal fee patent year 03
13.06.2019Renewal fee patent year 04
31.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.06.2016
AL19.05.2021
AT19.05.2021
CY19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
MT19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
[2024/41]
Former [2024/22]HU01.06.2016
AL19.05.2021
AT19.05.2021
CY19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2023/30]HU01.06.2016
AL19.05.2021
AT19.05.2021
CY19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2023/29]HU01.06.2016
AL19.05.2021
AT19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/29]AL19.05.2021
AT19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/26]AL19.05.2021
AT19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/23]AT19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/18]AT19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
LU01.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/10]AT19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/07]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/51]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/50]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
Former [2021/49]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
Former [2021/47]AT19.05.2021
FI19.05.2021
LT19.05.2021
BG19.08.2021
Former [2021/46]AT19.05.2021
FI19.05.2021
LT19.05.2021
Documents cited:Search[I]WO2015031775  (UNIV TEMPLE [US]) [I] 1-15 * pages 19-21 *;
 [A]  - W. HU ET AL, "RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20140721), vol. 111, no. 31, doi:10.1073/pnas.1405186111, ISSN 0027-8424, pages 11461 - 11466, XP055155740 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1405186111
 [A]  - KAMEL KHALILI ET AL, "Genome editing strategies: potential tools for eradicating HIV-1/AIDS", JOURNAL OF NEUROVIROLOGY, GB, (20150226), vol. 21, no. 3, doi:10.1007/s13365-014-0308-9, ISSN 1355-0284, pages 310 - 321, XP055534280 [A] 1-15 * pages 5-7; figure 4 *

DOI:   http://dx.doi.org/10.1007/s13365-014-0308-9
 [A]  - HIROTAKA EBINA ET AL, "Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus", SCIENTIFIC REPORTS, (20131201), vol. 3, no. 1, doi:10.1038/srep02510, XP055534219 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/srep02510
 [A]  - BRIAN WIGDAHL, "HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure", MOJ IMMUNOLOGY, (20141017), vol. 1, no. 4, doi:10.15406/moji.2014.01.00022, XP055534226 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.15406/moji.2014.01.00022
 [T]  - R KAMINSKI ET AL, "Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study", GENE THERAPY, GB, (20160801), vol. 23, no. 8 & 9, doi:10.1038/gt.2016.41, ISSN 0969-7128, pages 690 - 695, XP055534211 [T] * the whole document *

DOI:   http://dx.doi.org/10.1038/gt.2016.41
International search[X]WO2015031775  (UNIV TEMPLE [US]) [X] 1-4, 10, 11, 16-17, 19, 23-24, 26-27, 29-33, 38- 41, 48-49 * . Especially pg 2 para 2, pg 10 para 4, pg 11 para 4, pg 53 para 3, pg 54 para 2 sheet 1 fig 1C,D , sheet 14 Table S2, claim 89. *;
 [A]  - SAAYMAN et al., "The therapeutic application of CRISPR/Cas9 technologies for HIV.", Expert Opin Biol Ther, vol. 15, no. 6, pages 819 - 830, XP055408816 [A] 1-4, 10, 11, 16-17, 19, 23-24, 26-27, 29-33, 38- 41, 48, 49 * . Especially entire article (review). *

DOI:   http://dx.doi.org/10.1517/14712598.2015.1036736
by applicantUS5034506
 WO2015031775
    - MANJUNATH et al., Viruses, (20130000), vol. 5, no. 11, pages 2748 - 2766
    - STONE et al., Curr. Opin. HIV AIDS., (20130000), vol. 8, no. 3, pages 217 - 223
    - GAGNON JA et al., PLoS One, (20140000), vol. 9, no. 12, page el 15987
    - W. HU et al., "RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection", Proceedings of the National Academy of Sciences, (20140721), vol. Ill, no. 31, pages 11461 - 1146
    - KAMEL KHALILI et al., "Genome editing strategies: potential tools for eradicating HIV-1/AIDS", Journal of NeuroVirology, (20150226), vol. 21, no. 3, doi:10.1007/s13365-014-0308-9, pages 310 - 321, XP055534280

DOI:   http://dx.doi.org/10.1007/s13365-014-0308-9
    - HIROTAKA EBINA et al., "Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus", Scientific Reports, (20131201), vol. 3, no. 1, doi:10.1038/srep02510, XP055548923

DOI:   http://dx.doi.org/10.1038/srep02510
    - KORNBERG, A., Nucleotide Analogs, W. H. Freeman & Co., (19800000), pages 75 - 77
    - FREIERALTMANN, Nucl. Acid. Res., (19970000), vol. 25, no. 22, pages 4429 - 4443
    - TOULME, J.J., Nature Biotechnology, (20010000), vol. 19, pages 17 - 18
    - MANOHARAN M., Biochemica et Biophysica Acta, (19990000), vol. 1489, pages 117 - 139
    - FREIER S. M., Nucleic Acid Research, (19970000), vol. 25, pages 4429 - 4443
    - UHLMAN, E., Drug Discovery & Development, (20000000), vol. 3, pages 203 - 213
    - HERDEWIN P., Antisense & Nucleic Acid Drug Dev., (20000000), vol. 10, pages 297 - 310
    - N.K CHRISTIENSEN et al., J. Am. Chem. Soc., (19980000), vol. 120, pages 5458 - 5463
    - AIDS. HU et al., PNAS, (20140000), vol. 111, page 114616
    - "Genbank", Database accession no. KM099233.1
    - DE MESMAEKER et al., Acc. Chem. Res., (19950000), vol. 28, pages 366 - 374
    - NIELSEN et al., Science, (19910000), vol. 254, page 1497
    - GEBEYEHU, G. et al., Nucl. Acids Res., (19870000), vol. 15, page 4513
    - MANOHARAN et al., Bioorg. Med. Chem. Let., (19930000), vol. 3, pages 2765 - 278
    - LETSINGER et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, page 6553
    - MANOHARAN et al., Bioorg. Med. Chem. Let., (19940000), vol. 4, page 1053
    - MANOHARAN et al., Ann. N.Y. Acad. Sci., (19920000), vol. 660, page 306
    - OBERHAUSER et al., Nucl. Acids Res., (19920000), vol. 20, page 533
    - SAISON-BEHMOARAS et al., EMBO J., (19910000), vol. 10, page 111
    - KABANOV et al., FEES Lett., (19900000), vol. 259, page 327
    - SVINARCHUK et al., Biochimie, (19930000), vol. 75, page 49
    - MANOHARAN et al., Tetrahedron Lett., (19950000), vol. 36, page 3651
    - SHEA et al., Nucl. Acids Res., (19900000), vol. 18, page 3777
    - MANOHARAN et al., Nucleosides & Nucleotides, (19950000), vol. 14, page 969
    - MANNINOGOULD-FOGERITE, BioTechniques, (19880000), vol. 6, page 682
    - MAURER, R.A., Bethesda Res. Lab. Focus, (19890000), vol. 11, no. 2, page 25
    - HU P et al., Mol Ther Methods Clin Dev, (20150000), vol. 2, page 15025
    - LIU KC et al., Curr Gene Ther, (20140000), vol. 14, pages 3 52 - 364
    - SONG J et al., J Gen Virol, (20150000), vol. 96, pages 3131 - 3142
    - MADABHUSHI R et al., Cell, (20150000), vol. 161, pages 1592 - 1605
    - JADLOWSKY JK et al., Mol Cell Biol, (20140000), vol. 34, pages 1911 - 192
    - KOPP JB et al., Proc Natl Acad Sci U S A, (19920000), vol. 89, pages 1577 - 1581
    - HU W et al., Proc Natl Acad Sci USA, (20140000), vol. 111, pages 11461 - 11466
    - DOENCH JG et al., Nat Biotechnol, (20140000), vol. 32, pages 1262 - 1267
    - SANDER JD et al., Nat Biotechnol, (20110000), vol. 29, pages 697 - 698
    - QIU P et al., Biotechniques, (20040000), vol. 36, pages 702 - 707
    - YANG L et al., Nat Commun, (20140000), vol. 5, page 5507
    - DAHLEM TJ et al., PLoS Genet, (20120000), vol. 8, page el002861
    - BASSETT ARLIU JL, J Genet Genomics, (20140000), vol. 41, pages 7 - 19
    - GUELL M et al., Bioinformatics, (20140000), vol. 30, pages 2968 - 2970
    - BRINKMAN EK et al., Nucleic Acids Res, (20140000), vol. 42, page el68
    - RAMANAN V et al., Sci Rep, (20150000), vol. 5, page 10833
    - PENG CLU MYANG D, Virol Sin, (20150000), vol. 30, pages 317 - 325
    - ZUCKERMANN M et al., Nat Commun, (20150000), vol. 6, page 7391
    - VERES A et al., Cell Stem Cell, (20140000), vol. 15, pages 27 - 30
    - RAN FA et al., Nature, (20150000), vol. 520, pages 186 - 191
    - TSAI SQ et al., NatBiotechnol, (20150000), vol. 33, pages 187 - 197
    - FROCK RL et al., Nat Biotechnol, (20150000), vol. 33, pages 179 - 186
    - RAN FA et al., Cell, (20130000), vol. 154, pages 1380 - 1389
    - MALI P et al., Nat Biotechnol, (20130000), vol. 31, pages 833 - 838
    - WYVEKENS N et al., Hum Gene Ther, (20150000), vol. 26, pages 425 - 431
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.